Opsidio, LLC, a US-based clinical stage biotechnology company, announced on Wednesday that it has dosed its first subject in the Phase 2a clinical trial of OpSCF, the company's pioneering monoclonal antibody against stem cell factor, in subjects suffering from moderate to severe atopic dermatitis.
The company is collaborating with AbbVie for the development of OpSCF.
The study, a randomised, double-blind, placebo-controlled, Phase 2a study, is to assess the efficacy and safety of OpSCF in the treatment of adults with moderate to severe atopic dermatitis. The primary endpoint is the percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16, while the secondary endpoint comprises safety and tolerability and improvement in pruritus, body surface area, and quality of life.
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
Merck launches Phase 3 trial for dengue vaccine candidate V181
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Mezzion Pharma obtains USD20m funding for udenafil Phase 3 clinical development for Fontan patients
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
MaxCyte and Ori Biotech partner to advance autologous cell therapy manufacturing
OptiBiotix announces publication of positive SlimBiome study in European Journal of Nutrition
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies